Stocks-NOVO-B.CO-Novo Nordisk B A/S

NOVO-B.CO Novo Nordisk B A/S

912.92 23.82 (2.68%)
Marché ouverten DKK
Investissez
Stocks-NOVO-B.CO-Novo Nordisk B A/S
NOVO-B.CO Novo Nordisk B A/S
Investissez

Prix de Novo Nordisk B A/S

0.42% Semaine dernière
Created with Highcharts 4.2.7 /Highstock 4.2.7
Capitalisation boursière
3.93T
Plage de dates
910.23
-
922.11
Plage de 52S
613.18
-
1031.65
Volume (3M)
2.39M
Ratio cours/bénéfice
44.23
Revenu
258B

Dernières nouvelles Novo Nordisk B A/S

Voir tout
Novo Nordisk: va présenter ses avancées dans le diabèteNovo Nordisk: va présenter ses avancées dans le diabèteBoursoramaIl y a 6 joursForget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right NowForget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right NowThe Motley FoolIl y a 3 heuresNovo Nordisk experimental obesity pill has mild-to-moderate side effects in early trialNovo Nordisk experimental obesity pill has mild-to-moderate side effects in early trialLivemintIl y a un jour
Discussions Haut
burak0085
Danemark
Il y a 2 jours
Modifié
Part 9 GFI has experienced a challenging 2024, marked by a 20% production decline due to operational setbacks and adverse weather conditions. Despite this, the company reported positive cash flow from all operations and continues to focus on strategic growth. Notably, it made progress in its decarbonization... Afficher plus Traduction
J'aime CommentezPartagez
null
.
JordiReina
Espagne
Il y a 4 jours
Investment Opportunity: The 10 trillion Market for Weight Loss Drugs As obesity rates continue to rise globally, a significant investment opportunity is emerging in the weight loss pharmaceutical sector. Two major players, $NOVO-B.CO (Novo Nordisk B A/S) $GOLD and $LLY (Eli Lilly & Co) are leading... Afficher plus Traduction
J'aime CommentezPartagez
1 réponse
null
.
FabiGoesForGold
Allemagne
Il y a 6 jours
It has now been almost 5 years since I chose etoro as my main broker. In the meantime, individual stocks and sectors have emerged in my portfolio that are simply performing better and I'm not surprised that it's the medical and tech sectors. What surprises me is that Parker Hannifin has always... Afficher plus Traduction
J'aime CommentezPartagez
null
.
jwesth
Royaume Uni
Il y a 7 jours
𝙄𝙨 𝙂𝙪𝙗𝙧𝙖 𝙩𝙝𝙚 𝙣𝙚𝙭𝙩 𝙬𝙚𝙞𝙜𝙝𝙩 𝙡𝙤𝙨𝙨 𝙬𝙞𝙣𝙣𝙚𝙧? 📈 Danish biotech company $GUBRA.CO (Gubra A/S) has skyrocketed in 2024 and is suddenly on the radar of many retail investors. Since its listing on Nasdaq Copenhagen at a price of DKK 110 in March 2023, the share price has risen by... Afficher plus Traduction
J'aime CommentezPartagez
null
.
capimatt
Royaume Uni
Il y a 9 jours
Performance since Portfolio start in 2018: +100% ✅ Performance this year: +28% ✅ Target ROI: +30% annually ✅ 𝑬𝒕𝒐𝒓𝒐 𝑾𝒆𝒆𝒌𝒍𝒚 𝑼𝒑𝒅𝒂𝒕𝒆 - 𝑪𝒂𝒑𝒊𝒎𝒂𝒕𝒕 Hi Everyone. There is still lots of volatility around at the moment, and today has sparked a sell off to start the trading month in US... Afficher plus Traduction
J'aime CommentezPartagez
null
.
Brandt_2022
Danemark
Il y a 11 jours
🅱🆄🅸🅻🅳 🆈🅾🆄🆁 🅾🆆🅽 🅼🅾🅽🅴🆈 🆃🆁🅴🅴 💵 Dividend payments every month The dividend received in August comes from my wealth accumulation portfolio through passive income generated by stable and reliable companies. These companies have consistently increased or maintained their dividends for... Afficher plus Traduction
J'aime CommentezPartagez
1 réponse
null
.
robchamow
Espagne
Il y a 13 jours
📌 The Eurozone Moves Toward Stability: Inflation Hits Its Lowest Point Since 2021 📊Annual inflation in the Eurozone rose by 2.2% in August 2024, slowing down from the 2.6% recorded in July. This outcome, which aligns with market expectations, marks the most moderate increase in consumer prices since... Afficher plus Traduction
J'aime CommentezPartagez
null
.
jwesth
Royaume Uni
Il y a 15 jours
𝙉𝙤𝙫𝙤𝙣𝙚𝙨𝙞𝙨 𝙝𝙖𝙧 𝙚𝙣𝙙𝙚𝙡𝙞𝙜 𝙧𝙮𝙨𝙩𝙚𝙩 ‘𝙛𝙪𝙨𝙞𝙤𝙣𝙚𝙣𝙨 𝙛𝙤𝙧𝙗𝙖𝙣𝙙𝙚𝙡𝙨𝙚’ 𝙖𝙛 𝙨𝙞𝙜 👌 Et solidt halvårsresultat fra den danske ingrediens- og enzymproducent $NSIS-B.CO (Novonesis B) . Med en omsætning i første halvår på 1.944 mio. euro og et driftsresultat på 434 mio. euro... Afficher plus Traduction
J'aime CommentezPartagez
null
.
DanielDanick
Espagne
Il y a 15 jours
🔔🔔 $LLY (Eli Lilly & Co) launches new weight loss drug at lower price point 🔔🔔 Pharmaceutical company $LLY Lilly began offering initial doses of its low-cost weight loss drug, Zepbound, in single-dose vials, a move the company says will significantly increase the drug's availability. Its... Afficher plus Traduction
J'aime CommentezPartagez
null
.
TobiasGoris
Allemagne
Il y a 15 jours
$NSIS-B.CO (Novonesis B) the small sister of $NOVO-B.CO (Novo Nordisk B A/S) is my surprise portfolio staple: up by nearly 30 percent after the merger with Chr Hansen. Think of it as the biotech without human clinical application part of Novo Nordisk: novonesis is involved in the animal feed and nutrient... Afficher plus Traduction
J'aime CommentezPartagez
null
.

À propos de Novo Nordisk B A/S

La société Novo Nordisk B A/S, implantée à Bagsvaerd au Danemark, a été fondée en 1923. Cette entreprise médicale active à l’échelle mondiale se spécialise dans le traitement du diabète. L’action Novo Nordisk est négociée sur le CSE (Copenhagen Stock Exchange) sous le symbole NOVO-B.CO. Consultez le graphique du cours de l’action NOVO-B.CO sur eToro.
Lars Fruergaard Jørgensen, MBA
PDG
63.3K
Employés
1931
Fondée
DK
Siège
Show More
Technologie médicaleCopenhague

ESG : Une nouvelle source d'information

Qu'est-ce qu'un score ESG ?
Ce chiffre est une mesure de l'exposition d'une entreprise aux risques environnementaux, sociaux et de gouvernance. Les facteurs d'influence comprennent l'efficacité énergétique, la sécurité, les politiques sociales, etc. En savoir plus
Propulsé par ESG Book
Obtenez un aperçu de la durabilité d'une entreprise à l'aide des scores ESG (environnementaux, sociaux et de gouvernance).
0
100
52
Moyen
Secteur 
Moyenne 46 
55
Environnement
53
Social
48
Gouvernance
Business Involvement Flags
OGM
Les entreprises engagées dans la sélection végétale et animale, la génétique et la génomique, y compris les services de tests ADN sur les animaux et les plantes.
Propulsé par ESG Book

Les gens ont également acheté